|Bid||39.31 x 900|
|Ask||39.32 x 1200|
|Day's range||39.18 - 39.80|
|52-week range||31.43 - 48.25|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||39.58|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||1.89 (4.79%)|
|Ex-dividend date||14 May 2020|
|1y target est||48.67|
The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi <SASY.PA> and GSK <GSK.L> in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms. In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves will be bought by EU countries.
The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health
Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.